한글목차

개요

소아신경학은 신생아(신생아), 영아, 유아, 소년, 청소년의 신경장애를 발견하고 관리하는 전문 치료 분야입니다. 소아 신경 장비는 청소년의 신경학적 문제를 해결하는 데 사용되는 장비입니다. 소아 신경 장비에 사용되는 기술은 신경 질환을 치료하기 위해 개발된 기술입니다.

시장 역학: 시장 촉진요인과 시장 억제요인

제품 소개 증가

시장에 소아 신경 기기 도입이 증가함에 따라 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2023년 7월, Nicklaus Children's Hospital은 새로운 고밀도 뇌파(HD EEG) 시스템과 경두개 자기자극(TMS) 장치를 도입하여 소아 환자 치료를 위해 이 장치를 제공하는 국내 최고의 병원으로 발전했습니다.

또한, 2022년 10월 뉴로시그마는 소아 주의력 결핍 및 과잉행동장애(ADHD) 치료를 위한 모나크 eTNS 시스템과 이 개발에 대한 환자의 접근을 촉진하기 위한 소아과 치료 코페이 프로그램을 도입했습니다. 또한, 기술 발전, 인지도 향상, 사례 증가 등도 예측 기간 동안 세계 시장 성장에 기여할 것으로 예상됩니다.

높은 장비비용

신경 기기의 높은 비용은 예측 기간 동안 세계 시장 성장에 걸림돌이 될 것으로 예상됩니다. 예를 들어, 미주신경자극(VNS) 치료는 난치성 발작 환자를 치료하기 위해 확립된 방법이지만, 장치의 초기 비용이 약 1만 달러에 달하고 주기적으로 배터리를 교체해야 하기 때문에 전체 비용이 증가하여 세계 시장 성장을 둔화시키고 있습니다. 또한, 전문의 부족, 높은 제품 개발 비용 등이 예측 기간 동안 세계 시장의 성장을 둔화시키는 요인으로 작용하고 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 도입 증가
  • 성장 억제요인
    • 높은 기기 비용
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• 상환 분석
• 특허 분석
• 기술 동향
• 역학 분석
• SWOT 분석
• DMI 견해

제6장 COVID-19 분석

제7장 제품 유형별

• 신경자극 기기
• 신경외과용 기기
• 인터벤션 기기
• 골수액 관리 기기
• 기타 제품 유형

제8장 적응증별

• 발작
• 뇌졸중
• 수두증
• 신경종양학적 적응
• 기타 적응증

제9장 연령층별

• 0-5세
• 5-10세
• 10-15세

제10장 최종사용자별

• 병원
• 전문 클리닉
• 외래 수술 센터(ASC)
• 기타

제11장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제12장 경쟁 상황

• 경쟁 시나리오
• 시장 상황/점유율 분석
• M&A 분석

제13장 기업 개요

• Abbott Laboratories
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• LivaNova PLC
• Medtronic PLC, Inc.
• Natus Medical Inc.
• Stryker Corporation
• B.Barun SE
• Integra LifeSciences Corporation, Inc.
• Boston Scientific Corporation
• NeuroSigma, Inc.
• Zimmer Biomet

제14장 부록

영문목차

Overview

Pediatric neurology is addressed as a specialized component of treatment that deals with the detection and management of neurological disorders in neonates (newborns), infants, juveniles, and adolescents. Pediatric neurology devices are the instruments that are utilized to address neurological issues in youngsters. The technology employed in pediatric neurology devices is developed for curing neurological conditions.

Market Dynamics: Drivers & Restraints

Increase in Product Introductions

The increase in pediatric neurological device introductions into the market is expected to boost the global market growth during the forecast period. For instance, in July 2023, Nicklaus Children's Hospital introduced a new high-density electroencephalogram (HD EEG) system and transcranial magnetic stimulation (TMS) machine, evolving as one of the foremost in the country to deliver this equipment for the care of pediatric individuals.

Moreover, in October 2022, NeuroSigma introduced the Monarch eTNS System for treating pediatric attention-deficit/hyperactivity disorder (ADHD) and the Pediatric Care Copay program to promote patient access to the development. Furthermore, growing technological advancements, growing awareness and cases among other factors are also expected to contribute to the global market growth during the forecast period.

High Device Cost

The high cost of neurology devices is expected to hamper the global market growth during the forecast period. For instance, Vagus nerve stimulation (VNS) therapy is an established method for treating patients with refractory seizures, while the initial cost of the device is about 10,000 US dollars which again requires regular battery changes adding to the overall cost, slowing the global market growth. Furthermore, the lack of professional specialists and high product development costs among other additional factors are slowing the global market growth in the forecast period.

Segment Analysis

The global pediatric neurology devices market is segmented based on product type, indication, age group, end user and region.

Nerve Simulation Product Type is Expected to Dominate Market

Owing to the increase in new product introductions into the segment the nerve simulation product type is expected to hold the majority of the global market share during the forecast period. For instance, in February 2021, the FDA awarded 510(k) authorization to electroCore to extend the authorization of gammaCore, the corporation's non-invasive vagus nerve stimulation, for the acute and preventative therapy of adolescent migraine. Moreover, in February 2023, LivaNova PLC, a top medical technology and innovation corporation, introduced SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to deliver VNS Therapy in the treatment of drug-resistant epilepsy.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the increase in pediatric neurology device market developments in North America the region is expected to dominate the global market during the forecast period. For instance, in October 2022, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation, introduced the Monarch eTNS System the foremost medical device authorized by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD for pediatric patients (i.e., children ages 7-12), at the annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Toronto.

Also, in December 2022, Brain Scientific, a Florida-based applied science technology corporation, formed a new distribution agreement with MVAP Medical Supplies to push sales into the rapidly expanding and underserved pediatric EEG marketplace.

Further, in January 2023, NeuroSigma, Inc., a Los Angeles-based bioelectronics corporation trading external trigeminal nerve stimulation (eTNS) technology for the treatment of neurological and neuropsychiatric disorders, began a strategic digital marketing collaboration with Data360, a top provider of targeted, online marketing for the healthcare industry.

COVID-19 Impact Analysis

Various neurological manifestations have been associated with children's SARS-CoV-2 infection. It was crucial to identify and provide them with appropriate and timely treatment because they can be potentially serious and life-threatening, and some can lead to long-lasting consequences.

Different neuro-pathophysiological mechanisms were presented, but a causal relationship between SARS-CoV-2 infection and neurological manifestations stays unproven. COVID-19 affects patients with neurological diseases especially, not only by the disease itself but also by its complications and pandemic management measures, which has impacted the gbal market in a mixed way.

Market Segmentation

By Product Type

• Neurostimulation Devices
• Neurosurgery Devices
• Interventional Devices
• CSF Management Devices
• Other Product Types

By Indication

• Seizure
• Stroke
• Hydrocephalus
• Neurooncological Indications
• Other Indications

By Age Group

• 0-5 Years
• 5-10 Years
• 10-15 Years

By End User

• Hospital
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In June 2023, Biogen Inc. launched a new SPINRAZA (nusinersen) data strived to answer critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA.
• In October 2022, Axoft, a neurotechnology corporation, introduced and obtained the FDA Breakthrough Device designation for its brain-machine interface (BMI) to better treat neurological disorders.
• In October 2022, SpineX, Inc., a clinical-stage medtech corporation reported the groundbreaking results of its first in-human study in children with cerebral palsy.
• In January 2021, Theranica, a prescribed digital therapeutics (PDT) corporation obtained the Food and Drug Administration clearance to market its Nerivio therapeutic device for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, LivaNova PLC, Medtronic PLC, Natus Medical Inc., Stryker Corporation, B.Barun SE, Integra Lifesciences Corporation, Boston Scientific Corporation, Zimmer Biomet and NeuroSigma, Inc. among others.

Why Purchase the Report?

• To visualize the global pediatric neurology devices market segmentation based on product type, indication, age group, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pediatric neurology devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pediatric neurology devices market report would provide approximately 69 tables, 73 figures and 194 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Indication
• 3.3. Snippet by Age Group
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increase in Product Introductions
  • 4.1.2. Restraints
    • 4.1.2.1. High Device Cost
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Reimbursement Analysis
• 5.6. Patent Analysis
• 5.7. Technology Trend
• 5.8. Epidemiology
• 5.9. SWOT Analysis
• 5.10. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Neurostimulation Devices*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Neurosurgery Devices
• 7.4. Interventional Devices
• 7.5. CSF Management Devices
• 7.6. Other Product Types

8. By Indication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 8.1.2. Market Attractiveness Index, By Indication
• 8.2. Seizure*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Stroke
• 8.4. Hydrocephalus
• 8.5. Neurooncological Indications
• 8.6. Other Indications

9. By Age Group

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.1.2. Market Attractiveness Index, By Age Group
• 9.2. 0-5 Years*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. 5-10 Years
• 9.4. 10-15 Years

10. By End User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Hospital*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Ambulatory Surgical Centers (ASCs)
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Abbott Laboratories*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. LivaNova PLC
• 13.3. Medtronic PLC, Inc.
• 13.4. Natus Medical Inc.
• 13.5. Stryker Corporation
• 13.6. B.Barun SE
• 13.7. Integra LifeSciences Corporation, Inc.
• 13.8. Boston Scientific Corporation
• 13.9. NeuroSigma, Inc.
• 13.10. Zimmer Biomet

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us